Medicenna Therapeutics Corp

Research Medicenna Therapeutics Corp (MDNA) on Bullrun: market cap CAD 36.00M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerMDNA
• ExchangeTO
• CountryCanada
• SectorHealthcare
• IndustryBiotechnology
• CurrencyCAD
• Market capCAD 36.00M
• Financial periodQ4 2025
• Net income-CAD 4.36M
• Free cash flow-CAD 4.97M

Valuation Snapshot

latest market cap is CAD 36.00M.

About Medicenna Therapeutics Corp

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs;

Frequently asked questions

What is Medicenna Therapeutics Corp's market cap?

Medicenna Therapeutics Corp's market capitalization is CAD 36.00M.

What does Medicenna Therapeutics Corp do?

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases.